Cediranib maleate

Alias: NSC-732208 maleate; NSC 732208; AZD 2171 maleate; NSC732208; AZD2171; AZD-2171 maleate; Brand name: Recentin

Cat No.:V3282 Purity: ≥98%

COA Product Data Instructions for use SDS

Cediranib maleate(AZD-2171;Recenti, an indole ether quinazoline derivative), the maleate salt of Cediranib, is a novle and highly potent VEGFR (KDR) inhibitor with anticancer activity.

Cediranib maleate Chemical Structure CAS No.: 857036-77-2
Product category: VEGFR

This product is for research use only, not for human use. We do not sell to patients.

Size	Price	Stock	Qty
10mg
25mg
50mg
100mg
250mg
500mg
1g
Other Sizes

ADD TO CART CHECKOUT BULK INQUIRY

1-708-310-1919 sales@invivochem.com

Other Forms of Cediranib maleate:

Cediranib (NSC-732208; AZD-2171)

Official Supplier of:

Top Publications Citing lnvivochem Products

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

Purity & Quality Control Documentation

Current batch：

Purity: ≥98%

COA

MSDS

Instructions

Product Description
Bioactivity & Protocols
Physicochemical Properties
Solubility Data
Calculators
Clinical Trial Information
Biological Data

Product Description

Cediranib maleate (AZD-2171; Recenti, an indole ether quinazoline derivative), the maleate salt of Cediranib, is a novle and highly potent VEGFR (KDR) inhibitor with anticancer activity. In HUVEC cells, it exhibits >1000-fold selectivity for VEGFR over PDGFR-α, CSF-1R, and Flt3. It inhibits VEGFR with an IC50 of <1 nM. One promising therapeutic strategy is to inhibit vascular endothelial growth factor-A (VEGF) signaling, which aims to stop tumor-induced angiogenesis and stabilize the progression of solid malignancies. Cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGF-1,-2,-3) tyrosine kinases by competing with adenosine triphosphate. This prevents VEGF-signaling, angiogenesis, and tumor cell growth. Clinical trials are underway to develop cediranib as an oral medication to be taken once daily to treat cancer.

Biological Activity I Assay Protocols (From Reference)

Targets

Flt-1 (IC50 = 51 nM); KDR (IC50 = 1 nM); Flt-4 (IC50 = 3 nM); PDGFRα (IC50 = 36 nM); PDGFRβ (IC50 = 5 nM); c-Kit (IC50 = 2 nM)

ln Vitro

Cediranib inhibits KDR phosphorylation and VEGF-stimulated proliferation in human umbilical vein endothelial cells, with IC50 values of 0.4 and 0.5 nM, respectively. Cediranib also decreases vessel area, length, and branching at subnanomolar concentrations in a fibroblast/endothelial cell coculture model of vessel sprouting[1].

ln Vivo

Cediranib, when taken orally once a day, inhibits the development of corpora luteal in the ovary and ablates experimental (VEGF-induced) angiogenesis, two physiological processes that are heavily reliant on neovascularization. Cediranib inhibits the growth of human tumor xenografts (colon, lung, prostate, breast, and ovary) in athymic mice in a dose-dependent manner. In all models, a chronic dose of 1.5 mg per kg per day results in a statistically significant inhibition of tumor growth. Histologic examination of Calu-6 lung tumors treated with Cediranib shows a decrease in microvessel density after 52 hours of treatment, which increases over time. These alterations point to vascular regression occurring inside the tumors[1].

Enzyme Assay

ELISA methodology is used to assess Cediranib's inhibitory activity against a variety of recombinant tyrosine kinases, including KDR, Flt-1, Flt-4, c-Kit, PDGFR-α, PDGFR-β, CSF-1R, Flt-3, FGFR1, Src, Abl, epidermal growth factor receptor (EGFR), ErbB2, Aur-A, and Aur-B[1].

Cell Assay

PDGF-AA selectively activates PDGFR-α homodimer signaling, causing MG63 osteosarcoma cells to proliferate. Cells are grown for 24 hours in DMEM without phenol red, 2 mM glutamine, 1% nonessential amino acids, and 1% FCS stripped of charcoal. Plates are re-incubated for 72 hours after cediranib or the vehicle is added along with 50 ng/mL of PDGF-AA ligand. A bromodeoxyuridine is used to measure the proliferation of cells[1].

Animal Protocol

Rats: Cediranib (1.25–5 mg/kg/day) or vehicle is given orally to six-week-old female Wistar-derived Alderley Park rats (n = 5) once a day for 28 days. To investigate the effects of compound withdrawal, five more rats per group are treated for 28 days with either a vehicle or Cediranib (5 mg per kg per day) and then kept untreated for an additional 28 days. H&E is used to stain sections of the femorotibial joints and ovaries in histologic paraffin wax. The effect of compound treatment is analyzed using morphometric image analysis of femorotibial sections, combining growth plate areas from the tibia and femur in each joint. Similar to this, morphometric analysis is used to determine the area of corpora lutea in ovary sections stained with H&E[1].

References

[1]. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res, 2005, 65(10), 4389-4400.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Physicochemical Properties

Molecular Formula	C29H31FN4O7
Molecular Weight	566.59
Exact Mass	566.2176775
Elemental Analysis	C, 61.48; H, 5.52; F, 3.35; N, 9.89; O, 19.77
CAS #	857036-77-2
Related CAS #	Cediranib;288383-20-0
Appearance	Solid powder
SMILES	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5.C(=C\C(=O)O)\C(=O)O
InChi Key	JRMGHBVACUJCRP-BTJKTKAUSA-N
InChi Code	InChI=1S/C25H27FN4O3.C4H4O4/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30;5-3(6)1-2-4(7)8/h6-7,12-15,29H,3-5,8-11H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
Chemical Name	(Z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
Synonyms	NSC-732208 maleate; NSC 732208; AZD 2171 maleate; NSC732208; AZD2171; AZD-2171 maleate; Brand name: Recentin
HS Tariff Code	2934.99.9001
Storage	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility Data

Solubility (In Vitro)

DMSO: ~90 mg/mL (~199.8 mM)

Water: <1 mg/mL

Ethanol: <1 mg/mL

Solubility (In Vivo)

Solubility in Formulation 1: 2 mg/mL (3.53 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).

Solubility in Formulation 2: 5% DMSO+50% PEG 300+5% Tween+ddH2O: 5 mg/kg

(Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.7649 mL	8.8247 mL	17.6494 mL
	5 mM	0.3530 mL	1.7649 mL	3.5299 mL
	10 mM	0.1765 mL	0.8825 mL	1.7649 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Mass

Concentration

Volume

Molecular Weight*

Calculate Reset

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

Calculate the Mass of a compound required to prepare a solution of known volume and concentration
Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume

See Example

An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?

Enter 350.26 in the Molecular Weight (MW) box
Enter 10 in the Concentration box and choose the correct unit (mM)
Enter 5 in the Volume box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Concentration (Start)

Volume (Start)

Concentration (End)

Volume (End)

Calculate Reset

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:

Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
Enter 25 into the Concentration (End) box and select the correct unit (mM)
Enter 25 into the Volume (End) box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box

Molecular formula

Total molecular weight

g/mol

Calculate Reset

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4 c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Calculate Reset

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
Click the “Calculate” button
The answer appears in the Volume (to add to vial) box

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)

Dosage mg/kg

Average weight of animals g

Dosing volume per animal μL

Number of animals

Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)

% DMSO

% Tween 80

% ddH₂O

Calculate Reset

Calculation results

Working concentration： mg/mL；

Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O，mix and clarify.

Note： (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01116648	Active Recruiting	Drug: Cediranib Maleate Procedure: Biopsy	Ovarian High Grade Serous Adenocarcinoma Fallopian Tube Carcinoma	National Cancer Institute (NCI)	April 14, 2010	Phase 1 Phase 2
NCT02974621	Active Recruiting	Drug: Cediranib Drug: Cediranib Maleate	Recurrent Glioblastoma	National Cancer Institute (NCI)	January 10, 2020	Phase 2
NCT01364051	Active Recruiting	Drug: Cediranib Drug: Cediranib Maleate	Refractory Malignant Solid Neoplasm Metastatic Melanoma	National Cancer Institute (NCI)	May 25, 2011	Phase 1
NCT01064648	Active Recruiting	Drug: Cediranib Maleate Drug: Cisplatin	Epithelioid Mesothelioma Sarcomatoid Mesothelioma	National Cancer Institute (NCI)	March 15, 2010	Phase 1 Phase 2
NCT02345265	Active Recruiting	Drug: Cediranib Maleate Procedure: Biopsy	Fallopian Tube Carcinoma Ovarian Carcinoma	National Cancer Institute (NCI)	May 17, 2016	Phase 2

Biological Data

AZD2171 inhibits VEGF-stimulated KDR phosphorylation in human endothelial cells.Cancer Res.2005 May 15;65(10):4389-400.
AZD2171 inhibits tubule growthin vitro. HUVECs and human fibroblasts were obtained as commercial cocultures (AngioKit, TCS Cellworks).Cancer Res.2005 May 15;65(10):4389-400.
AZD2171 inhibits VEGF-induced angiogenesisin vivo.Cancer Res.2005 May 15;65(10):4389-400.
Consequences of inhibiting VEGF signaling and physiologic angiogenesisin vivo: effect of AZD2171 on bone morphogenesis and ovarian cycling in young female rats.Cancer Res.2005 May 15;65(10):4389-400.
AZD2171 inhibits human tumor xenograft growth at doses that are well tolerated.Cancer Res.2005 May 15;65(10):4389-400.
AZD2171 causes vascular regression in Calu-6 lung tumor xenografts.Cancer Res.2005 May 15;65(10):4389-400.